A primary short opportunity is identified in ATYR Pharma (LIFE) ahead of its pivotal trial data in mid-September, which is expected to be negative. Another high-conviction short is D-Wave (QBTS), which is viewed as a flawed business with a potential price target near $1 due to declining core revenue. This skepticism extends to the entire Quantum Computing sector, including IONQ and RGTI, which is considered a hype-driven bubble. A smaller short position is held in Joby Aviation (JOBY) based on a massive valuation that appears disconnected from its potential market size. In contrast, a bullish view is held on General Electric (GE), specifically citing its jet engine division as a very high-quality business.

D-Wave (QBTS)

• The speaker, Martin Shkreli, has a bearish view on D-Wave, calling it a "scumbag company" and an "uber scam." He holds a significant short position in the stock.
• Earnings & Revenue: He notes that D-Wave had a "rough quarter" despite beating revenue expectations. He explains the beat was due to a one-time system sale to a customer in Germany, not from their core cloud business.
  • The Quantum Computing as a Service (QCaaS) revenue, their cloud offering, has been dropping sequentially, from $1.7M last year to $1.2M in the most recent quarter.
  • He suggests this is because the German customer who bought a system no longer needs to use D-Wave's cloud and can offer access to others, cannibalizing D-Wave's own service.
• Business Model Concerns: He is highly skeptical of their "quantum annealing" technology, suggesting it offers no real speed advantage over classical computers and that the company is a "fraud."
  • He finds it very suspicious that D-Wave will not let just anyone use their cloud computer, unlike other cloud providers (AWS, Azure, etc.). He believes they pre-screen customers to prevent anyone from proving the machine doesn't work as advertised.
• Financials: The company has burned $35 million so far this year but has significant cash reserves. Shkreli questions what they will do with the capital, suggesting the business itself is "worthless."
  • The company has 338 million shares outstanding, which he considers a huge amount, indicating significant shareholder dilution.
• Price Target: He believes the stock is going to go down to its cash value, which he estimates at $2 per share, but says "maybe $5." He also mentions it will be at "$1 soon."

Takeaways

• High Risk Short Opportunity: The speaker presents a strong bearish case against D-Wave, viewing it as a potential short sale candidate based on what he perceives as a flawed business model, declining core revenues, and questionable technology.
• Scrutinize Revenue Sources: Investors should look past headline revenue beats and analyze the source of the revenue. The decline in the recurring QCaaS business is a significant red flag according to the speaker.
• Beware of Dilution: The massive number of shares outstanding is a concern. Future capital raises could further dilute existing shareholders' stakes.
• Fundamental vs. Hype: The stock appears to be trading on hype around quantum computing rather than on its fundamental business performance, which the speaker sees as deteriorating.

ATYR Pharma (LIFE)

• The speaker is extremely bearish on ATYR Pharma and believes its lead drug has "no chance" of success in its upcoming clinical trial. This is his largest short position and a major "binary event" trade for him.
• Clinical Trial pessimism: He states there is a "0% chance the drug works" and compares it to past failed companies like Cassava.
  • He believes the drug lacks a plausible mechanism of action. In biotech, if a drug doesn't have a clear scientific reason for why it should work and also lacks strong early-stage data, it's very likely to fail in larger, more rigorous Phase 3 trials.
  • He notes that trial results rarely get better going from Phase 2 to Phase 3; they usually get weaker.
• Red Flag: The company raised money just before their pivotal clinical trial data was due to be released. The speaker sees this as a major red flag, implying that management lacks confidence in the outcome and wanted to secure cash before a potential stock price collapse.
• Timeline: The trial data is expected in mid-September.

Takeaways

• High-Risk Binary Event: ATYR represents a high-risk, high-reward "binary event" trade. The stock's value is almost entirely dependent on the outcome of its upcoming clinical trial.
• Bearish Catalyst: A negative trial result, which the speaker is convinced will happen, would likely cause the stock to fall dramatically. This is the core of his short thesis.
• Contrarian View: Investors who are long the stock should be aware of this strong bearish argument, particularly the points about the lack of a clear mechanism and the pre-data financing.

Sarepta Therapeutics (SRPT)

• The speaker details his trading history in Sarepta, which has been highly volatile but ultimately profitable for him. His sentiment is currently bullish, though he acknowledges the risks.
• Trading Strategy: He employed a "value investing" or "averaging down" strategy.
  • He began building a small position.
  • The stock dropped significantly on very bad news (a patient death in a trial).
  • Instead of selling everything, he saw a crisis as an opportunity and continued to buy more as the price fell, building his position up to a maximum of 17% of his portfolio. He compares this to Warren Buffett's famous investment in American Express during the "Salad Oil Scandal."
  • He eventually sold the entire position ("capitulated") for a ~9% portfolio loss.
  • He then re-entered the stock just two weeks before it doubled, and is now sitting on a large gain. His current position is 14% of his portfolio.
• Conviction: The strategy of buying a stock as it falls is extremely risky and only works if the investor's core thesis about the company's long-term value remains intact despite the negative news. The speaker felt he understood the situation better than the market.

Takeaways

• Crisis Investing: Sarepta serves as a case study in "crisis investing." Sometimes, market overreactions to bad news can create buying opportunities for investors with high conviction and a strong stomach for volatility.
• Position Sizing is Key: The speaker, despite his conviction, managed his position size. He started small and gradually increased his exposure. He notes that at its peak, the position was 17% of his portfolio, which is highly concentrated.
• Profit Taking: After a massive run-up (he mentions buying at $10.55 and the stock now being at $18), he is considering trimming his position to manage risk. This is a crucial discipline for investors who have a large gain in a volatile stock.

Quantum Computing Sector (IONQ, RGTI)

• The speaker is extremely bearish on the entire publicly traded quantum computing sector for the foreseeable future. He believes it is a bubble built on hype.
• Core Thesis: Quantum computers are not the all-powerful, universally fast machines they are portrayed to be.
  • They are a million to a billion times slower than classical computers (like those from NVIDIA) at basic operations.
  • Their only advantage is a theoretical speedup for one specific algorithm (Shor's algorithm), which is used for factoring large numbers. The primary use for this is breaking current forms of cryptography.
  • He believes a useful quantum computer is 20-30 years away.
• IonQ (IONQ): He is bearish on IonQ's strategy.
  • He views their acquisitions as a sign of desperation and a pivot away from their core business, which he believes is not progressing.
  • He mocks the CEO's claims that IonQ will be as big as Cisco or NVIDIA.
  • He points out that the company's own founder and Chief Scientific Officer, Chris Monroe, has made public statements suggesting a useful quantum computer is decades away, contradicting the CEO.
• Rigetti (RGTI): He is also short Rigetti but seems to view them as the "most honest" of the group.
  • He respects that Rigetti's management has publicly stated that anyone claiming real revenue from quantum computing right now is lying.

Takeaways

• Sector-Wide Skepticism: Investors should be highly skeptical of the near-term commercial viability of quantum computing companies. The technology is likely decades away from having a meaningful business impact.
• Bubble Characteristics: The sector exhibits classic bubble characteristics: revolutionary technology promises, massive stock price increases on little to no revenue, and a disconnect from fundamental reality.
• Look for Red Flags: Pay attention to management commentary. Conflicting statements between executives and scientists (as seen with IonQ) are a major red flag. Pivoting into new business lines via acquisition can also be a sign that the core business is failing.

Joby Aviation (JOBY)

• The speaker holds a small bearish short position in Joby.
• Valuation Concerns: His primary issue is the company's massive valuation (mentioned as $16 billion market cap) compared to its lack of revenue (mentioned as $15,000).
• Flawed Business Model: He is not convinced that Joby's electric vertical take-off and landing (eVTOL) vehicles offer a significant advantage over traditional helicopters.
• Market Size: He argues that the entire existing market for helicopter manufacturing and helicopter ferry services (like Blade) is smaller than Joby's current market cap, suggesting the valuation is completely detached from the potential size of the business.

Takeaways

• Concept vs. Reality: Joby is a "concept stock." Investors are betting on a future vision, not a current business. The risk is that this vision never materializes or is much smaller than anticipated.
• Valuation Sanity Check: When evaluating pre-revenue companies, it's crucial to assess the total addressable market (TAM). If the company's valuation exceeds the entire existing market it aims to disrupt, it is a significant red flag.

Other Notable Mentions

• MicroStrategy (MSTR): The speaker describes the company as "bizarre" and "a little crazy." His concern is that it operates as a levered investment fund for Bitcoin without being registered as one, which could pose regulatory risks.
• General Electric (GE): He has a bullish view on the jet engines business, calling it a "very good business" with an "insane moat."
• INmuno Bio (INMB): This was a highly successful short position for the speaker. It was his single biggest winner, contributing 43% to his portfolio's performance. He went "all in" on the trade.
• Abivax (ABVX): This was a successful long position. He bought it as a "momentum" trade after it had already gone up 300%, and it continued to rise.
• Kohl's (KSS): Mentioned as another successful short trade.

Investment Strategy: "Binary Events"

• The speaker outlines a specific investment strategy he uses, focusing on what he calls "binary events" or "special situations."
• The Strategy:
  • Identify a future event where the outcome will have a dramatic, make-or-break impact on a company's stock price. Clinical trial results for biotech companies are a prime example.
  • Do deep research to develop extremely high conviction on the outcome. He emphasizes patience, stating he only makes a couple of these bets per year.
  • He focuses on shorting, looking for "the worst of the worst" companies with drugs that he believes are "impossible" to work.
  • When he finds such an opportunity, he bets in "large size."
• Examples: He cites ATYR Pharma (LIFE) as his current binary event trade and Cassava Sciences (SAVA) as a successful past example.

Takeaways

• High-Risk, Expert Strategy: This is an extremely high-risk strategy that is not suitable for most investors. It requires deep domain expertise (in his case, pharmaceuticals and clinical trials) and the ability to withstand significant volatility.
• The Power of Catalysts: The core idea is to find specific, date-driven catalysts that will force the market to re-evaluate a company's worth. For retail investors, being aware of upcoming catalysts for stocks in their portfolio (like earnings dates, FDA decisions, or trial results) is a valuable takeaway.